Teladoc Health (NYSE:TDOC) Full Year 2024 Results

Key Financial Results

• Revenue: US$2.57b (down 1.3% from FY 2023).
• Net loss: US$1.00b (loss widened by 354% from FY 2023).
• US$5.87 loss per share (further deteriorated from US$1.34 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Teladoc Health Meets Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations.

The primary driver behind last 12 months revenue was the Integrated Care segment contributing a total revenue of US$1.53b (59% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to US$910.8m (32% of total expenses). Explore how TDOC's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 9.7% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's shares are down 17% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Teladoc Health that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.